Market Access News | pharmaphorum

News

GSK's RSV shot cleared in US for all adults

GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

News

NHS cleared to use Astellas' non-hormonal menopause drug

Around half a million women will soon be able to access Astellas' Veoza treatment for symptoms like hot flushes associated with menopause.

News

NICE says no to Genmab cervical cancer therapy

Genmab's recently approved therapy for relapsed cervical cancer has been turned down for NHS use in initial NICE guidance.

News

Multicoloured letters with AUTISM spelled in the middle

FDA approves leucovorin – but not for autism

The FDA stops short of approving leucovorin for autism, but will its clearance for ultra-rare condition CFD-FOLR1 lead to more off-label prescribing?

News

FDA cuts testing requirements for biosimilars once again

The FDA has issued additional guidance that aims to make it easier for drugmakers to bring biosimilars of patent-expired biologic drugs to market.

News

Incyte breaks new ground in anal cancer with EU approval

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

GSK's RSV shot cleared in US for all adults

NHS cleared to use Astellas' non-hormonal menopause drug

NICE says no to Genmab cervical cancer therapy

FDA approves leucovorin – but not for autism

FDA cuts testing requirements for biosimilars once again

Incyte breaks new ground in anal cancer with EU approval

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks